不可切除III期NSCLC携带少见基因组变异患者同步放化疗后辅助度伐利尤单抗治疗
这项多中心回顾性研究纳入271例不可切除III期NSCLC患者,其中130例接受辅助度伐利尤单抗。全体人群中位PFS为接受度伐利尤单抗者24.9个月 vs 未接受者12.6个月(p=0.001);在携带少见驱动基因组变异(排除常见EGFR突变)患者中,中位PFS为12.3个月 vs 7.6个月(p=0.038)。作者认为KRAS突变和少见驱动基因组变异患者可从辅助度伐利尤单抗获得有意义的生存获益,但需进一步前瞻性研究确认。
要点
- 全体患者中位PFS:接受辅助度伐利尤单抗者24.9个月 vs 未接受者12.6个月(p=0.001)。
- 少见驱动基因组变异组(排除常见EGFR突变)中位PFS:接受度伐利尤单抗者12.3个月 vs 未接受者7.6个月(p=0.038)。
- KRAS突变和少见驱动基因组变异患者中位PFS差异未达统计学显著(p=0.12和p=0.23)。
核心结论
- 在携带KRAS突变和少见驱动基因组变异的不可切除III期NSCLC患者中,辅助度伐利尤单抗显示出有意义的生存获益。
- 这是目前显示度伐利尤单抗在少见驱动基因组变异患者中疗效的最大III期NSCLC队列。
- 需要进一步前瞻性研究来确认本研究结果。
研究设计与样本
- 多中心(荷兰和意大利,共4个中心)回顾性研究,纳入2016年至2022年间连续接受同步放化疗(联合或不联合辅助度伐利尤单抗)的不可切除III期NSCLC患者。
- 共纳入271例患者,其中130例接受辅助度伐利尤单抗。
- 66例患者携带驱动基因组变异:41例KRAS突变、4例EGFR常见突变、21例少见驱动基因组变异。
主要发现
- 全体人群中位PFS:接受辅助度伐利尤单抗者24.9个月(95%CI 17.5-32.4) vs 未接受者12.6个月(95%CI 9.0-16.1),p=0.001。
- 驱动基因组变异组(排除常见EGFR突变)中位PFS:接受辅助度伐利尤单抗者12.3个月(95%CI 7.8-16.8) vs 未接受者7.6个月(95%CI 3.4-11.9),p=0.038。
- KRAS突变患者中位PFS:接受辅助度伐利尤单抗者12.3个月(95%CI 3.6-20.9) vs 未接受者7.2个月(95%CI 1.8-12.6),p=0.12。
- 少见驱动基因组变异患者中位PFS:接受辅助度伐利尤单抗者12.9个月(95%CI 8.4-17.4) vs 未接受者7.6个月(95%CI 1.4-14),p=0.23。
局限性
- 原文指出需要进一步前瞻性研究来确认本研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adjuvant durvalumab is the standard of care for patients with stage III unresectable non-small cell lung cancer (NSCLC), without progression after concurrent chemo-radiation (CCRT). Patients with stage III NSCLC harbouring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements do not seem to benefit from durvalumab. Data are lacking about patients harbouring other driver genomic alterations (dGA). We performed a multicentre (N = 4, Netherlands and Italy) retrospective study including consecutive patients with unresectable stage III NSCLC and treated with CCRT-with or without adjuvant durvalumab-between 2016 and 2022. We enrolled 271 patients; 130 of which received adjuvant durvalumab. Sixty-six patients had dGA (41 KRAS mutations, 4 EGFR common mutations and 21 uncommon dGA). In the entire population, the median PFS was 24.9 months (95% CI 17.5-32.4) and 12.6 months (95% CI 9.0-16.1) with and without durvalumab (p = 0.001). In the dGA group (excluding common EGFR), mPFS was 12.3 months (95% CI 7.8-16.8) with and 7.6 (95% CI 3.4-11.9) without durvalumab (p = 0.038). For patients with KRAS mutations, mPFS was 12.3 months (95% CI 3.6-20.9) with and 7.2 months (95% CI 1.8-12.6) without durvalumab (p = 0.12). Among patients with uncommon dGA, mPFS was 12.9 months (95% CI 8.4-17.4) with and 7.6 months (95% CI 1.4-14) without durvalumab (p = 0.23). We have shown a meaningful survival benefit of adjuvant durvalumab in patients harbouring KRAS mutations and uncommon dGA. This is the largest stage III NSCLC cohort showing the efficacy of durvalumab in patients with uncommon dGA. Further prospective studies are needed to confirm our results.
引用
- Cortiula F, De Ruysscher D, Steens M, et al. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. Eur J Cancer. 2023. PMID: 36931075. doi:10.1016/j.ejca.2023.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。